Evidence map›Paper›PMID 35691027›Full record

ArticleHepatology communications2022

A single hepatitis B virus genome with a reporter allows the entire viral life cycle to be monitored in primary human hepatocytes.

Ariunaa Sumiyadorj, Kazuhisa Murai, Tetsuro Shimakami, Kazuyuki Kuroki, Tomoki Nishikawa, Masaki Kakuya, Atsumu Yamada, Ying Wang, Atsuya Ishida, Takayoshi Shirasaki and 11 more

Open access · goldAbstract read
In one paragraph

Article in Hepatology communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 2 countries.

Ariunaa SumiyadorjDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Kazuhisa MuraiDepartment of Clinical Laboratory Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Tetsuro ShimakamiDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Kazuyuki KurokiDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Tomoki NishikawaDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Masaki KakuyaDepartment of Clinical Laboratory Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Atsumu YamadaDepartment of Clinical Laboratory Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Ying WangDepartment of Clinical Laboratory Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Atsuya IshidaDepartment of Clinical Laboratory Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Takayoshi ShirasakiDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Shotaro KawaseDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Ying-Yi LiDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Hikari OkadaDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Kouki NioDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Kazunori KawaguchiDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Taro YamashitaDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Yoshio SakaiDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Davaadorj DugerDepartment of Gastroenterology, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.
Eishiro MizukoshiDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Masao HondaDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.ORCID 0000-0003-3050-5854
Shuichi KanekoDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Kanazawa University · JPMongolian National University · MN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For the development of antiviral agents to eliminate hepatitis B virus (HBV), it is essential to establish an HBV cell culture system that can easily monitor HBV infection. Here, we created a novel HBV infection monitoring system using a luminescent 11-amino acid reporter, the high-affinity subunit of nano-luciferase binary technology (HiBiT). The HiBiT-coding sequence was inserted at the N-terminus of preS1 in a 1.2-fold plasmid encoding a genotype C HBV genome. After transfection of HepG2 cells with this HiBiT-containing plasmid, the supernatant was used to prepare a recombinant cell culture-derived virus (HiBiT-HBVcc). Primary human hepatocytes (PXB) were inoculated with HiBiT-HBVcc. Following inoculation, intracellular and extracellular HiBiT activity and the levels of various HBV markers were determined. Reinfection of naive PXB cells with HiBiT-HBVcc prepared from HiBiT-HBVcc-infected PXB cells was analyzed. When PXB cells were infected with HiBiT-HBVcc at several titers, extracellular HiBiT activity was detected in a viral titer-dependent manner and was correlated with intracellular HiBiT activity. Inhibitors of HBV entry or replication suppressed extracellular HiBiT activity. Viral DNA, RNA, and proteins were detectable, including covalently closed circular DNA, by Southern blot analysis. The synthesis of relaxed-circular DNA from single-stranded DNA in HiBiT-HBV decreased to one third of that of wild-type HBV, and the infectivity of HiBiT-HBVcc decreased to one tenth of that of wild-type HBVcc. HiBiT-HBVcc prepared from PXB cells harboring HiBiT-HBV was able to infect naive PXB cells. Conclusions: Recombinant HiBiT-HBV can undergo the entire viral life cycle, thus facilitating high-throughput screening for HBV infection in vitro using supernatants. This system will be a powerful tool for developing antiviral agents.

Indexed as

Hepatitis BHepatitis B virusAnimalsAntiviral AgentsDNA, CircularHepatocytesHumansLife Cycle StagesVirus ReplicationAntiviral AgentsDNA, Circular

Identifiers

PMID35691027
PMCPMC9426382
OpenAlexW4282587048

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.